Literature DB >> 25345736

A systematic microdialysis study of dopamine transmission in the accumbens shell/core and prefrontal cortex after acute antipsychotics.

Gianluigi Tanda1, Valentina Valentini, Maria Antonietta De Luca, Valentina Perra, Gian Pietro Serra, Gaetano Di Chiara.   

Abstract

RATIONALE: The only systematic in vivo studies comparing antipsychotic (AP) effects on nucleus accumbens (NAc) shell and core dopamine (DA) transmission are voltammetric studies performed in pargyline-pretreated, halothane-anaesthetized rats. Studies in freely moving rats not pretreated with pargyline are not available. This study was intended to fill this gap by the use of in vivo microdialysis in freely moving rats.
METHODS: Male Sprague-Dawley rats were implanted with microdialysis probes in the NAc shell and core and medial prefrontal cortex (PFCX). The next day, rats were administered intravenously with two or three doses of APs, and dialysate DA was monitored in 10-min samples. Some rats were pretreated with pargyline (75 mg/kg i.p.) and after 1 h were given clozapine or risperidone.
RESULTS: Clozapine, risperidone, quetiapine, raclopride, sulpiride and amisulpride increased DA preferentially in the NAc shell. Such preferential effect on shell DA was not observed after haloperidol, chlorpromazine and olanzapine. In contrast to voltammetric studies, a preferential effect on NAc core DA was not observed after any dose of AP. Pargyline pretreatment did not reduce but actually amplified the preferential effect of clozapine and risperidone on NAc shell DA.
CONCLUSIONS: Apart from raclopride and olanzapine, the APs with lower extrapyramidal effects could be distinguished from typical APs on the basis of their ability to preferentially stimulate DA transmission in the NAc shell. There was no relationship between stimulation of PFCX DA and atypical APs profile. The differences between this study and voltammetry studies were not attributable to pargyline pretreatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25345736     DOI: 10.1007/s00213-014-3780-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  79 in total

Review 1.  Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.

Authors:  S Kapur; P Seeman
Journal:  Am J Psychiatry       Date:  2001-03       Impact factor: 18.112

Review 2.  Pharmacokinetics of clozapine and risperidone: a review of recent literature.

Authors:  M J Byerly; C L DeVane
Journal:  J Clin Psychopharmacol       Date:  1996-04       Impact factor: 3.153

3.  Sulpiride versus haloperidol in schizophrenia: a double-blind comparative trial.

Authors:  G B Cassano; P Castrogiovanni; L Conti; L Bonollo
Journal:  Curr Ther Res Clin Exp       Date:  1975-02

4.  Halothane attenuated haloperidol and enhanced clozapine-induced dopamine release in the rat striatum.

Authors:  Yushi U Adachi; Yoshihiko Aramaki; Maiko Satomoto; Hideyuki Higuchi; Kazuhiko Watanabe
Journal:  Neurochem Int       Date:  2003-07       Impact factor: 3.921

5.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats.

Authors:  Martin Johnson; Magdalena Kozielska; Venkatesh Pilla Reddy; An Vermeulen; Cheryl Li; Sarah Grimwood; Rik de Greef; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Pharm Res       Date:  2011-06-07       Impact factor: 4.200

Review 6.  Antipsychotic occupancy of dopamine receptors in schizophrenia.

Authors:  Magdalena Nord; Lars Farde
Journal:  CNS Neurosci Ther       Date:  2010-12-08       Impact factor: 5.243

7.  Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens.

Authors:  J Ichikawa; T Kuroki; J Dai; H Y Meltzer
Journal:  Eur J Pharmacol       Date:  1998-06-19       Impact factor: 4.432

8.  Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine.

Authors:  G S Robertson; H C Fibiger
Journal:  Neuroscience       Date:  1992       Impact factor: 3.590

9.  A dopamine-mu1 opioid link in the rat ventral tegmentum shared by palatable food (Fonzies) and non-psychostimulant drugs of abuse.

Authors:  G Tanda; G Di Chiara
Journal:  Eur J Neurosci       Date:  1998-03       Impact factor: 3.386

10.  Imaging dopamine transmission in the frontal cortex: a simultaneous microdialysis and [11C]FLB 457 PET study.

Authors:  R Narendran; H P Jedema; B J Lopresti; N S Mason; K Gurnsey; J Ruszkiewicz; C-M Chen; L Deuitch; W G Frankle; C W Bradberry
Journal:  Mol Psychiatry       Date:  2013-02-26       Impact factor: 15.992

View more
  12 in total

1.  Adolescent stress leads to glutamatergic disturbance through dopaminergic abnormalities in the prefrontal cortex of genetically vulnerable mice.

Authors:  Yurie Matsumoto; Minae Niwa; Akihiro Mouri; Yukihiro Noda; Takeshi Fukushima; Norio Ozaki; Toshitaka Nabeshima
Journal:  Psychopharmacology (Berl)       Date:  2017-07-29       Impact factor: 4.530

2.  Distinctive Modulation of Dopamine Release in the Nucleus Accumbens Shell Mediated by Dopamine and Acetylcholine Receptors.

Authors:  Jung Hoon Shin; Martin F Adrover; Veronica A Alvarez
Journal:  J Neurosci       Date:  2017-10-13       Impact factor: 6.167

3.  Effects of dopamine modulation on chronic stress-induced deficits in reward learning.

Authors:  Steven J Lamontagne; Sarah I J Wash; Samantha H Irwin; Kate E Zucconi; Mary C Olmstead
Journal:  Cogn Affect Behav Neurosci       Date:  2022-04-08       Impact factor: 3.526

Review 4.  Preclinical studies on the reinforcing effects of cannabinoids. A tribute to the scientific research of Dr. Steve Goldberg.

Authors:  Gianluigi Tanda
Journal:  Psychopharmacology (Berl)       Date:  2016-03-30       Impact factor: 4.530

5.  Early Antipsychotic Treatment in Juvenile Rats Elicits Long-Term Alterations to the Dopamine Neurotransmitter System.

Authors:  Michael De Santis; Jiamei Lian; Xu-Feng Huang; Chao Deng
Journal:  Int J Mol Sci       Date:  2016-11-22       Impact factor: 5.923

6.  Neurophysiological and Neurochemical Effects of the Putative Cognitive Enhancer (S)-CE-123 on Mesocorticolimbic Dopamine System.

Authors:  Claudia Sagheddu; Nicholas Pintori; Predrag Kalaba; Vladimir Dragačević; Gessica Piras; Jana Lubec; Nicola Simola; Maria Antonietta De Luca; Gert Lubec; Marco Pistis
Journal:  Biomolecules       Date:  2020-05-18

7.  Comparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation Antipsychotics.

Authors:  Kirk E Evoy; Chengwen Teng; Victor G Encarnacion; Brian Frescas; John Hakim; Stephen Saklad; Christopher R Frei
Journal:  Subst Abuse       Date:  2019-05-01

Review 8.  Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.

Authors:  Willem Johan van den Brink; Semra Palic; Isabelle Köhler; Elizabeth Cunera Maria de Lange
Journal:  Pharm Res       Date:  2018-02-15       Impact factor: 4.200

Review 9.  Toward whole-brain dopamine movies: a critical review of PET imaging of dopamine transmission in the striatum and cortex.

Authors:  Heather Liu; Yasmin Zakiniaeiz; Kelly P Cosgrove; Evan D Morris
Journal:  Brain Imaging Behav       Date:  2019-04       Impact factor: 3.978

Review 10.  Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review.

Authors:  Fabrizio Schifano; Stefania Chiappini; John M Corkery; Amira Guirguis
Journal:  Brain Sci       Date:  2018-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.